Sign In
Buy APTX
$0.0960
+0 (+0%)
At Close: Mar 28, 2024
Apotex Health Corp. (APTX) Opens the Market
11:17am, Thursday, 11'th Jun 2026
Toronto, Ontario--(Newsfile Corp. - June 11, 2026) - Jeff Watson, President and Chief Executive Officer, Apotex Health Corp. (Apotex) (TSX: APTX) along with its Board of Directors, executive team, par
Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO
08:00am, Tuesday, 23'rd Apr 2024
SAN DIEGO--(BUSINESS WIRE)--Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two dec
Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives
04:05pm, Thursday, 30'th Mar 2023
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022. Recent Business Updates In March, A
Here's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock Now
11:23am, Thursday, 30'th Mar 2023
After losing some value lately, a hammer chart pattern has been formed for Aptinyx Inc. (APTX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate re
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
01:00pm, Tuesday, 21'st Mar 2023
COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.
Why Is Aptinyx (APTX) Stock Down 64% Today?
08:36am, Tuesday, 28'th Feb 2023
Aptinyx (NASDAQ: APTX ) stock is taking a beating on Tuesday after the company revealed results from a Phase 2 clinical trial. The bad news here is that this clinical trial failed to meet its primary
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to
Aptinyx to Present at the SVB Securities Global Biopharma Conference
07:47am, Tuesday, 31'st Jan 2023
EVANSTON, Ill.--( BUSINESS WIRE )--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,
Preclinical Data from Aptinyx's NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience
07:45am, Thursday, 10'th Nov 2022
EVANSTON, Ill.
Aptinyx Inc. (APTX) CEO Andy Kidd on Q3 2022 Results - Earnings Call Transcript
09:46pm, Tuesday, 08'th Nov 2022
Aptinyx Inc. (NASDAQ:APTX ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corporate Development & IR Andy Kidd - President and CEO
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
04:05pm, Tuesday, 08'th Nov 2022
EVANSTON, Ill.
Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant
07:30am, Thursday, 03'rd Nov 2022
EVANSTON, Ill.
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
07:45am, Tuesday, 18'th Oct 2022
EVANSTON, Ill.
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to
Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal
12:48pm, Friday, 12'th Aug 2022
Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline
